Cerebrospinal fluid biomarkers in Guillain-Barré syndrome – Where do we stand?

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Neurology

• Publication date

  2009-02-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00415-009-0097-xPMID 19267167
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Guidelines for the next 10 years of proteomics

  2009cited by this paper
• Axonal Guillain‐Barré syndrome: carbohydrate mimicry and pathophysiology

  2007cited by this paper
• The polypeptide composition of moving and stationary neurofilaments in cultured sympathetic neurons.

  2007cited by this paper
• CSF tau protein: a new prognostic marker for Guillain-Barre syndrome.

  2007influential reference
• Comparison of two ELISA methods for measuring levels of the phosphorylated neurofilament heavy chain.

  2007cited by this paper
• Proteomic identification of potential protein markers in cerebrospinal fluid of GBS patients

  2007cited by this paper
• Proteome analysis of cerebrospinal fluid in Guillain-Barré syndrome (GBS).

  2007influential reference
• Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis

  2006cited by this paper
• Axonal damage markers in cerebrospinal fluid are increased in ALS

  2006cited by this paper
• Detection of CSF 14-3-3 protein in Guillain–Barré syndrome

  2006influential reference
• CSF neurofilament levels: A potential prognostic marker in Guillain–Barré syndrome

  2006influential reference
• The Neurofilament Heavy Chain (NfHSMI35) in the Cerebrospinal Fluid Diagnosis of Alzheimer’s Disease

  2006cited by this paper
• Anti‐ganglioside antibodies and elevated CSF IgG levels in Guillain‐Barré syndrome

  2006cited by this paper
• CSF tau protein: A new prognostic marker for Guillain-Barré syndrome

  2006cited by this paper
• An enzyme immunoassay to quantify neurofilament light chain in cerebrospinal fluid.

  2005cited by this paper
• Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study

  2005cited by this paper
• REporting recommendations for tumour MARKer prognostic studies (REMARK)

  2005cited by this paper
• SeminarGuillain-Barré syndrome

  2005cited by this paper
• Isolated blood–cerebrospinal fluid barrier dysfunction: prevalence and associated diseases

  2005influential reference
• Guillain-Barré syndrome

  2004cited by this paper
• Demonstration of oligoclonal immunoglobulin G in Guillain-Barré syndrome and lymphocytic meningoradiculitis by isoelectric focusing

  2004cited by this paper
• Advances in understanding and treatment of immune‐mediated disorders of the peripheral nervous system

  2004cited by this paper
• Ganglioside complexes as new target antigens in Guillain–Barré syndrome

  2004cited by this paper
• The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration.

  2003cited by this paper
• Guillain–Barré syndrome with marked pleocytosis or a significant proportion of polymorphonuclear granulocytes in the cerebrospinal fluid: neuropathological investigation of five cases and review of differential diagnoses

  2003cited by this paper
• CSF hypocretin levels in Guillain–Barré syndrome and other inflammatory neuropathies

  2003cited by this paper
• A specific ELISA for measuring neurofilament heavy chain phosphoforms.

  2003cited by this paper
• Guillain-Barré syndrome

  2003cited by this paper
• CSF and serum levels of soluble fractalkine (CX3CL1) in inflammatory diseases of the nervous system.

  2003cited by this paper
• Aberrated Levels of Cerebrospinal Fluid Chemokines in Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyradiculoneuropathy

  2003cited by this paper
• The STARD Statement for Reporting Studies of Diagnostic Accuracy: Explanation and Elaboration

  2003cited by this paper
• Quality of life complements traditional outcome measures in immune-mediated polyneuropathies

  2002cited by this paper
• Peripheral neuropathies and anti-glycolipid antibodies.

  2002cited by this paper
• Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10.

  2002cited by this paper
• Neuron-specific enolase and S100B in cerebrospinal fluid after severe traumatic brain injury in infants and children.

  2002cited by this paper
• CSF hypocretin/orexin levels in narcolepsy and other neurological conditions

  2001cited by this paper
• Tau protein in cerebrospinal fluid (CSF): a blood-CSF barrier related evaluation in patients with various neurological diseases.

  2001cited by this paper
• Diagnostic and Classification Criteria for the Guillain-Barré Syndrome

  2001cited by this paper
• Early electrodiagnostic findings in Guillain-Barré syndrome.

  2001cited by this paper
• Minimum information about a microarray experiment (MIAME)—toward standards for microarray data

  2001cited by this paper
• Cystatin C and cathepsin B in CSF from patients with inflammatory neurologic diseases

  2000influential reference
• Expression of TNFα and TGFβ1 in Guillain–Barré syndrome: correlation of a low TNFα‐/TGFβ1‐mRNA ratio with good recovery and signs for immunoregulation within the cerebrospinal fluid compartment

  2000cited by this paper
• Expression of TNFalpha and TGFbeta1 in Guillain-Barré syndrome: correlation of a low TNFalpha-/TGFbeta1-mRNA ratio with good recovery and signs for immunoregulation within the cerebrospinal fluid compartment.

  2000cited by this paper
• Prognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange

  1999cited by this paper
• The 14-3-3 Protein Detectable in the Cerebrospinal Fluid of Patients with Prion-Unrelated Neurological Diseases Is Expressed Constitutively in Neurons and Glial Cells in Culture

  1999cited by this paper
• The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis

  1998cited by this paper
• Molecular Mimicry in Guillain‐Barré Syndrome a

  1998cited by this paper
• The soluble 60-kDa tumour necrosis factor receptor: no difference found between patients with relapsing-remitting multiple sclerosis and controls: increasing levels are associated with the recovery from Guillain-Barré syndrome

  1998influential reference
• Electrophysiological classification of guillain‐barré syndrome: Clinical associations and outcome

  1998cited by this paper
• Cerebrospinal fluid - physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases

  1998cited by this paper
• Guillain-Barré syndrome in Taiwan: a clinical study of 167 patients

  1997cited by this paper
• Cytokine pattern in the cerebrospinal fluid from patients with GBS and CIDP.

  1997influential reference
• S-100 protein concentration in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease

  1997cited by this paper
• Patients with Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases Have Increased Levels of Neurofilament Protein in CSF

  1996cited by this paper
• Acute motor axonal neuropathy: An antibody‐mediated attack on axolemma

  1996influential reference
• Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barré syndrome

  1996cited by this paper
• Guillain-Barré syndrome in northern China. The spectrum of neuropathological changes in clinically defined cases.

  1995influential reference
• Increased CSF C4d in demyelinating neuropathy indicates the radicular involvement

  1995cited by this paper
• Campylobacter jejuni infection and Guillain-Barré syndrome.

  1995cited by this paper
• Prognostic value of cerebrospinal fluid neuron‐specific enolase and S‐100b protein in Guillain‐Barré syndrome

  1994influential reference
• Prognostic factors in Guillain-Barre' syndrome.

  1994cited by this paper
• Cerebrospinal fluid protein concentrations related to clinical findings in patients with sciatica caused by disk herniation.

  1994cited by this paper
• Serum and CSF anti-GM1 antibodies in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy.

  1993influential reference
• Interleukin-6 levels in the cerebrospinal fluid and serum of patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy.

  1993cited by this paper
• Comparative analysis of cytokine patterns in immunological, infectious, and oncological neurological disorders.

  1991influential reference
• Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain‐Barré syndrome

  1991cited by this paper
• A clinicopathological study of the Guillain-Barré syndrome. Nine cases and literature review.

  1991cited by this paper
• Clinical signs in severe Guillain-Barré syndrome: analysis of 63 patients.

  1991cited by this paper
• Cerebrospinal fluid and serum antiphospholipid antibodies in multiple sclerosis, Guillain-Barré syndrome and systemic lupus erythematosus.

  1990cited by this paper
• Detection of neuron specific enolase concentrations in cerebrospinal fluid from patients with neurological disorders by means of a sensitive enzyme immunoassay.

  1990influential reference
• A prospective study of acute idiopathic neuropathy. I. Clinical features and their prognostic value.

  1988cited by this paper
• Guillain‐barré syndrome

  1987influential reference
• Clinical significance of serum and CSF findings in the Guillain-Barré syndrome and related disorders

  1986cited by this paper
• Activated terminal complement in cerebrospinal fluid in Guillain-Barré syndrome and multiple sclerosis.

  1986cited by this paper
• Anti-peripheral myelin antibody in patients with demyelinating neuropathy: quantitative and kinetic determination of serum antibody by complement component 1 fixation.

  1985cited by this paper
• Calcitonin gene-related peptide immunoreactivity in the spinal cord of man and of eight other species

  1984cited by this paper
• Complement activation by isolated myelin: activation of the classical pathway in the absence of myelin-specific antibodies.

  1982cited by this paper
• Pathology of the Guillain‐Barré syndrome

  1981cited by this paper
• Purification and properties of a brain-specific protein, human 14-3-3 protein.

  1980cited by this paper
• Controlled trial prednisolone in acute polyneuropathy.

  1978cited by this paper
• Residua of Guillain-Barré Polyneuritis in Children.

  1977cited by this paper
• Early predictors of incomplete recovery in children with Guillain-Barr'e polyneuritis.

  1975cited by this paper
• The anatomy of the blood brain barrier: a review.

  1972cited by this paper
• Ultrastructural observations in Guillain-Barre syndrome.

  1972cited by this paper
• The anatomy of the blood brain barrier: a review.

  1972cited by this paper

• Hematological Parameters, Biochemical Findings and Cerebrospinal Fluid Profiles among Guillan-Barre Syndrome Patients

  2025cites this paper
• Comparison of serum antinuclear antibodies in Guillain–Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy: a retrospective case–control study

  2025cites this paper
• Clinical Insights Into Anti‐Sulfatide Antibodies in Peripheral Neuropathies: A Retrospective Study

  2025cites this paper
• Guillain‐Barré syndrome following COVID‐19 vaccination: An updated systematic review of cases

  2023cites this paper
• CSF in Guillain-Barré Syndrome

  2023cites this paper
• Factors Predicting Prolonged Mechanical Ventilation in Guillain–Barré Syndrome

  2023cites this paper
• CSF, Blood, and MRI Biomarkers in Skogholt’s Disease—A Rare Neurodegenerative Disease in a Norwegian Kindred

  2023cites this paper
• The early clinical and laboratory predictors of GBS outcome: hospital-based study, Assiut University, Upper Egypt

  2023cites this paper
• Prognostic Implications of Early Albuminocytological Dissociation in Guillain–Barré Syndrome

  2022cites this paper
• Characteristic cerebrospinal fluid findings in immune checkpoint inhibitor-related peripheral neuropathy: A case report.

  2022cites this paper
• Glial cells and neurologic autoimmune disorders

  2022cites this paper
• Acute onset Chronic Inflammatory Demyelinating Neuropathy Following COVID-19

  2022cites this paper
• Case report: Incidence and prognostic value of brain MRI lesions and elevated cerebrospinal fluid protein in children with Guillain-Barré syndrome

  2022cites this paper
• Cerebrospinal Fluid Analysis.

  2021cites this paper
• Clinical and biochemical profile of Guillain Barré Syndrome in Pakistan

  2021cites this paper
• Covid-19 associated Guillain-Barré syndrome: A series of a relatively uncommon neurological complication

  2021cites this paper
• Potential biomarkers identified by tandem mass tags based quantitative proteomics for diagnosis and classification of Guillain–Barré syndrome

  2021cites this paper
• Electrophysiological patterns in patient with Guillain-Barre syndrome

  2021cites this paper
• Glycolysis and Autoimmune Diseases: A Growing Relationship

  2020cites this paper
• Cerebrospinal fluid findings and hypernatremia in COVID-19 patients with altered mental status

  2020cites this paper
• Guillain–Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases

  2020cites this paper
• Guillain Barré Syndrome and its variants as a manifestation of COVID-19: A systematic review of case reports and case series

  2020cites this paper
• Outcomes of Guillain–Barré Syndrome Patients Admitted to Intensive Care Unit in Tertiary Care Hospital

  2019cites this paper
• Early predictors of functional disability in Guillain–Barré Syndrome

  2019cites this paper
• Analysis of Neuron-Specific Enolase of Cerebrospinal Fluid and Post Mortem Serum of Blunt Head Trauma in Cause and Time of Death Determination

  2019cites this paper
• Cerebrospinal Fluid Protein Level and Nerve Conduction Study as Short-Term Prognostic Marker of Guillain Barré Syndrome

  2018cites this paper
• Adding a temporal dimension to the study of Friedreich's ataxia: the effect of frataxin overexpression in a human cell model

  2018cites this paper
• Identification of CSF biomarkers by proteomics in Guillain-Barré syndrome

  2018cites this paper
• Identification of cardioprotective drugs by medium-scale in vivo pharmacological screening on a Drosophila cardiac model of Friedreich's ataxia

  2018cites this paper
• Transplantation of wild-type mouse hematopoietic stem and progenitor cells ameliorates deficits in a mouse model of Friedreich’s ataxia

  2017cites this paper
• Tumor necrosis factor-α in Guillain-Barré syndrome, friend or foe?

  2017cites this paper
• Strategien zur Subklassifizierung Guillain-Barré-artiger Polyneuropathien bei Hund und Katze

  2017cites this paper
• Cerebrospinal fluid findings in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathies.

  2017cites this paper
• Early VGLUT1-specific parallel fiber synaptic deficits and dysregulated cerebellar circuit in the KIKO mouse model of Friedreich ataxia

  2017cites this paper
• A Case of Guillain-Barre Syndrome with Significant Lymphocytic Pleocytosis

  2017cites this paper
• The use of cerebrospinal fluid in biomarker studies.

  2017cites this paper
• Dentate Update: Imaging Features of Entities That Affect the Dentate Nucleus

  2017cites this paper
• Effect of Cornus officinalis glycosides on the myelin basic protein in blood serum and the nerve function in Balb/c mice after sciatic nerve injury

  2017cites this paper
• Degenerative ataxias, from genes to therapies

  2016cites this paper
• Proposed diagnostic criteria for cerebellar ataxia with neuropathy and vestibular areflexia syndrome (CANVAS)

  2016cites this paper
• Lentivirus-meditated frataxin gene delivery reverses genome instability in Friedreich ataxia patient and mouse model fibroblasts

  2016cites this paper
• Deletion of the GAA repeats from the human frataxin gene using the CRISPR-Cas9 system in YG8R-derived cells and mouse models of Friedreich ataxia

  2016cites this paper
• Activating frataxin expression by repeat-targeted nucleic acids

  2016cites this paper
• Time-resolved functional analysis of acute impairment of frataxin expression in an inducible cell model of Friedreich ataxia

  2016cites this paper
• A new cellular model to follow Friedreich's ataxia development in a time-resolved way

  2015cites this paper
• PERCENTAGE OF PATIENTS WHO SHOW AGREEMENT BETWEEN EMG AND CSF FINDINGS FOR THE DIAGNOSIS OF GBS

  2015cites this paper
• Association of ubiquitin carboxy-terminal hydrolase-L1 in cerebrospinal fluid with clinical severity in a cohort of patients with Guillain–Barré syndrome

  2015cites this paper
• Biomarkers of Guillain-Barré Syndrome: Some Recent Progress, More Still to Be Explored

  2015cites this paper
• CSF Findings in Guillain-Barré Syndrome: Demyelinating and Axonal Acute Inflammatory Polyneuropathies

  2015cites this paper
• A novel GAA-repeat-expansion-based mouse model of Friedreich’s ataxia

  2015cites this paper
• Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria.

  2014cites this paper
• Comparison of electrophysiological findings in axonal and demyelinating Guillain-Barre syndrome

  2014cites this paper
• Increased cerebrospinal fluid protein and motor conduction studies as prognostic markers of outcome and nerve ultrasound changes in Guillain-Barré syndrome.

  2014cites this paper
• A study of up to 12 years of follow-up of Friedreich ataxia utilising four measurement tools

  2014cites this paper
• Autoantibodies against ganglioside GM3 are associated with narcolepsy-cataplexy developing after Pandemrix vaccination against 2009 pandemic H1N1 type influenza virus.

  2014cites this paper
• Cerebrospinal fluid cystatin C levels following treatment for aneurysmal subarachnoid hemorrhage.

  2014cites this paper
• CRITICAL CARE NEUROLOGY AND NEURO CRITICAL CARE

  2014cites this paper
• Alpha-Synuclein and 14-3-3 Proteins as Biomarkers of Neurodegenerative Diseases

  2014cites this paper
• Elevated levels of S100B, tau and pNFH in cerebrospinal fluid are correlated with subtypes of Guillain-Barresyndrome

  2013cites this paper
• Increased prevalence of sleep-disordered breathing in Friedreich ataxia

  2013cites this paper
• Endoscopic Associated Iatrogenic Terson's Syndrome

  2013cites this paper
• Evaluating the Status of Antiganglioside Antibodies in Children with Guillain-Barré Syndrome

  2013cites this paper
• Elevated levels of S100B, tau and pNFH in cerebrospinal fluid are correlated with subtypes of Guillain–Barré syndrome

  2013influential citation
• Friedreich's ataxia–associated GAA repeats induce replication-fork reversal and unusual molecular junctions

  2013cites this paper
• The role of chemokines in guillain–barré syndrome

  2013cites this paper
• Assessment of cerebrospinal fluid parameters in the diagnosis of neurological diseases

  2013cites this paper
• Serial cerebrospinal fluid neurofilament heavy chain levels in severe Guillain‐Barré syndrome

  2013cites this paper
• Posterior Spinal Fusion for Friedreich Ataxia-Related Scoliosis in Twin Girls: A Case Report.

  2013cites this paper
• 14-3-3 proteins, particularly of the epsilon isoform, are detectable in cerebrospinal fluids of cerebellar diseases in children.

  2013cites this paper
• Biochemical markers of autoimmune diseases of the nervous system.

  2012cites this paper
• Recent developments and future directions in Guillain‐Barré syndrome

  2012cites this paper
• Understanding the genetic and molecular pathogenesis of Friedreich’s ataxia through animal and cellular models

  2012cites this paper
• Interferon gamma upregulates frataxin and corrects the functional deficits in a Friedreich ataxia model

  2012cites this paper
• Altered cerebrospinal fluid index of prealbumin, fibrinogen, and haptoglobin in patients with Guillain–Barré syndrome and chronic inflammatory demyelinating polyneuropathy

  2012cites this paper
• The Heart in Friedreich Ataxia: Definition of Cardiomyopathy, Disease Severity, and Correlation With Neurological Symptoms

  2012cites this paper
• Kidney infarction in Friedreich's ataxia with dilated cardiomyopathy

  2012cites this paper
• Normal left ventricular ejection fraction and mass but subclinical myocardial dysfunction in patients with Friedreich's ataxia.

  2012cites this paper
• Clinical Reasoning: A middle-aged woman with progressive symmetric weakness and a CSF pleocytosis

  2012cites this paper
• A case of anti-GA1 antibody-positive Fisher syndrome with elevated tau protein in cerebrospinal fluid.

  2012cites this paper
• [Miller-Fisher variant of Guillain-Barré syndrome in the Resuscitation Unit].

  2012cites this paper
• Neurons and cardiomyocytes derived from induced pluripotent stem cells as a model for mitochondrial defects in Friedreich’s ataxia

  2012cites this paper
• Autosomal recessive cerebellar ataxias: the current state of affairs

  2011cites this paper
• The peripheral cerebrospinal fluid outflow pathway – physiology and pathophysiology of CSF recirculation: A review and hypothesis

  2011cites this paper
• Síndrome de Guillain-Barré em associação temporal com a vacina influenza A

  2011cites this paper
• ADEM as a niche variant of post infectious neurological syndromes.

  2011cites this paper
• Multiple cranial neuropathy variant of guillain–barré syndrome: A case series

  2011cites this paper
• Silencing of frataxin gene expression triggers p53-dependent apoptosis in human neuron-like cells.

  2011cites this paper
• What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 1: acute and monophasic diseases.

  2011cites this paper
• The cerebellar cognitive profile.

  2011cites this paper
• Altered lipid metabolism in a Drosophila model of Friedreich's ataxia

  2010cites this paper
• Iron-binding activity in yeast frataxin entails a trade off with stability in the alpha1/beta1 acidic ridge region.

  2010cites this paper
• Tumor necrosis factor-alpha polymorphisms and expression in Guillain-Barré syndrome.

  2010cites this paper
• Long intronic GAA repeats causing Friedreich ataxia impede transcription elongation

  2010cites this paper
• Understanding the molecular mechanisms of Friedreich's ataxia to develop therapeutic approaches.

  2010cites this paper
• Peripheral neuropathies: Biomarkers for axonal damage in immune-mediated neuropathy

  2009cites this paper
• Clinically Silent Posterior Reversible Encephalopathy in Guillain-Barré Syndrome

  year unknowncites this paper